Healthcare provider profile · identity verified

Karin Coetzee Moolman, M.D.

Family Practice · NASHVILLE, TN · NPI 1396965034

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	474	126
Atorvastatin Calcium	Atorvastatin Calcium	425	118
Zolpidem Tartrate	Zolpidem Tartrate	338	58
Amlodipine Besylate	Amlodipine Besylate	298	90
Losartan Potassium	Losartan Potassium	296	84
Rosuvastatin Calcium	Rosuvastatin Calcium	268	81
Alprazolam	Alprazolam	188	31
Lisinopril	Lisinopril	160	50
Clonazepam	Clonazepam	156	29
Trazodone Hcl	Trazodone Hcl	149	46
Pravastatin Sodium	Pravastatin Sodium	148	46
Metoprolol Succinate	Metoprolol Succinate	146	37
Gabapentin	Gabapentin	143	32
Omeprazole	Omeprazole	139	46
Lorazepam	Lorazepam	135	21
Simvastatin	Simvastatin	131	39
Hydrochlorothiazide	Hydrochlorothiazide	127	40
Fluticasone Propionate	Fluticasone Propionate	121	50
Duloxetine Hcl	Duloxetine Hcl	112	28
Estradiol	Estradiol	101	32
Ramipril	Ramipril	98	27
Meloxicam	Meloxicam	95	38
Sertraline Hcl	Sertraline Hcl	91	27
Metformin Hcl	Metformin Hcl	90	24
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	89	28
Pantoprazole Sodium	Pantoprazole Sodium	86	28
Bupropion Xl	Bupropion Hcl	82	30
Fluoxetine Hcl	Fluoxetine Hcl	78	20
Montelukast Sodium	Montelukast Sodium	78	22
Pregabalin	Pregabalin	78	13
Escitalopram Oxalate	Escitalopram Oxalate	75	28
Olmesartan Medoxomil	Olmesartan Medoxomil	74	24
Ozempic	Semaglutide	71	14
Metformin Hcl Er	Metformin Hcl	69	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	68	18
Albuterol Sulfate Hfa	Albuterol Sulfate	67	24
Esomeprazole Magnesium	Esomeprazole Magnesium	67	22
Ibandronate Sodium	Ibandronate Sodium	65	22
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	62	13
Synthroid	Levothyroxine Sodium	62	20
Citalopram Hbr	Citalopram Hydrobromide	58	18
Furosemide	Furosemide	54	14
Metoprolol Tartrate	Metoprolol Tartrate	51	14
Trulicity	Dulaglutide	50	suppressed
Valsartan	Valsartan	50	14
Diazepam	Diazepam	45	suppressed
Jardiance	Empagliflozin	45	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	45	14
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	44	13
Mounjaro	Tirzepatide	44	suppressed
Mirtazapine	Mirtazapine	43	suppressed
Azelastine Hcl	Azelastine Hcl	41	24
Fenofibrate	Fenofibrate Nanocrystallized	41	suppressed
Glimepiride	Glimepiride	39	suppressed
Tramadol Hcl	Tramadol Hcl	39	suppressed
Allopurinol	Allopurinol	37	15
Telmisartan	Telmisartan	36	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	31	26
Ezetimibe	Ezetimibe	31	suppressed
Irbesartan	Irbesartan	31	suppressed
Methylprednisolone	Methylprednisolone	30	28
Eszopiclone	Eszopiclone	29	suppressed
Solifenacin Succinate	Solifenacin Succinate	28	suppressed
Spironolactone	Spironolactone	28	suppressed
Eliquis	Apixaban	27	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	27	suppressed
Propranolol Hcl	Propranolol Hcl	27	suppressed
Atenolol	Atenolol	26	suppressed
Azithromycin	Azithromycin	26	24
Glipizide	Glipizide	26	suppressed
Ondansetron Odt	Ondansetron	26	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	25	suppressed
Valacyclovir	Valacyclovir Hcl	25	15
Mometasone Furoate	Mometasone Furoate	24	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	23
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	23	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Fluconazole	Fluconazole	23	19
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Carisoprodol	Carisoprodol	21	suppressed
Famotidine	Famotidine	21	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	21	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	21	21
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	suppressed
Myrbetriq	Mirabegron	20	suppressed
Acyclovir	Acyclovir	19	suppressed
Cefuroxime	Cefuroxime Axetil	19	17
Celecoxib	Celecoxib	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Temazepam	Temazepam	19	suppressed
Carvedilol	Carvedilol	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Potassium Chloride	Potassium Chloride	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Repatha Sureclick	Evolocumab	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	15	suppressed
Fenofibrate	Fenofibrate,micronized	15	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Doxepin Hcl	Doxepin Hcl	14	suppressed
Progesterone	Progesterone, Micronized	14	suppressed
Promethazine Hcl	Promethazine Hcl	14	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Finasteride	Finasteride	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Premarin	Estrogens, Conjugated	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Prednisone	Prednisone	12	12
Baclofen	Baclofen	11	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Fentanyl	Fentanyl	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error